[Evaluation of thrombotic risk in young men after myocardial infarction during a period of clinical stability].
The study was aimed at an evaluation of individualized indications for antithrombotic therapy for secondary prevention in a group of 40 young survivors (aged 30-40 years) of myocardial infarction, presenting a stable phase of coronary disease. The control group consisted of 19 healthy men, of approximately similar age distribution. The determinations concerned the following: in vitro ADP and collagen induced platelet aggregation, plasma fibrinogen concentration, factor VII, VIII and antithrombin III activity, protein C concentration, spontaneous fibrinolytic activity and fibrinolytic activity after venostasis, plasminogen and alpha-2 antiplasmin activity. Moreover, to determine correlations with hemostatic parameters lipids, apolipoproteins, glucose, uric acid plasma concentration as well as percentages of lipoproteins and glycolyzed hemoglobin were also studied. In the study group various hemostasis disturbances were found: an increased platelet aggregation induced by low concentrations of ADP, increased plasma fibrinogen concentration and factor VII activity, decreased protein C concentration and impaired plasma fibrinolytic activity after venostasis. Some correlations between hemostatic and lipids parameters were also observed. Results of the study have suggested necessity for the individualized antithrombotic prevention in young survivors of myocardial infarction with antiplatelet and/or anticoagulant drugs.
Elikowski
W
W
Kliniki Chorób Wewnetrznych, Poznaniu.
Zozulińska
M
M
Psuja
P
P
Turowiecka
Z
Z
Lewandowski
K
K
Przybył
L
L
Zawilska
K
K
D000328:Adult; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012008:Recurrence; D012307:Risk Factors
D005343:Fibrinolytic Agents
Ocena zagrozenia zakrzepowego u młodych mezczyzn po zawale serca w okresie klinicznej stabilności.